AI model predicts pancreatic cancer risk 3 years before diagnosis
· Medical Xpressby American College of Surgeons
edited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
The GIST Add as preferred source
Researchers at Mayo Clinic have designed an artificial intelligence model that could predict an individual's risk of developing pancreatic cancer years before diagnosis. The research was presented at the American College of Surgeons (ACS) Clinical Congress 2026 in Washington, Sept. 26–29.
Pancreatic cancer is relatively rare but highly deadly, with about 67,000 new diagnoses and 52,000 deaths in 2026, according to the American Cancer Society. It accounts for about 3% of all new cancers but 8% of all cancer deaths.
"Pancreatic cancer can be curable, but only when we catch it early—and fewer than one in five patients is diagnosed in time," said study co-author Cornelius Thiels, DO, MBA, FACS, a surgical oncologist at Mayo Clinic in Rochester, Minnesota. "As a result, survival for many patients is still measured in months, not years."
Universal screening for pancreatic cancer isn't feasible, Thiels said, so his team set out to develop an AI model that can identify patients at greatest risk of developing cancer of the pancreas.
"We know that pancreatic cancer forms over five to seven years, but the things that a clinician or patient sees don't happen until it's too late," he said.
The model Thiels, lead study author Chris Varghese, MBChB, and their team developed used patients' longitudinal health histories—detailed information in their electronic health records that provides a picture of their health over time—from the Mayo Clinic system. The model combined that data with results of routine laboratory tests obtained over an average of a decade or more.
The study dataset included 6,066 individuals with pancreatic cancer and 33,396 controls with 7.5 to 19 years of clinical histories. The goal was to identify subtle clues that could point to a risk of pancreatic cancer early on, Thiels said.
To test the model's ability to predict pancreatic cancer three years before diagnosis, the researchers calculated the area under the receiver operating characteristic (AUROC) curve, which measures how well the model distinguishes between people at risk for pancreatic cancer and those at low risk. The AUROC was 0.853, on a scale where 1.0 represents perfect discrimination and 0.5 is no better than chance.
The model also showed a strong ability to identify patients truly at risk while limiting false positives, with an area under the precision-recall curve (AUPRC) of 0.712.
The study also showed the model was well calibrated, meaning its predicted risk closely matched what actually happened, with a calibration plot slope of 1.08. "Our model showed that a greater than 50% risk of pancreas cancer predicted by our model indicated an 88% likelihood of being diagnosed with pancreatic cancer in one year," said Varghese, a surgical data scientist at Mayo Clinic in Rochester.
"We built this to be as generalizable, scalable, and easy to put into practice as possible," Varghese added. The data inputs the model relies on are captured almost universally in hospital systems worldwide, he said. "If it's shown to work, it could be used in almost any setting," he added.
The researchers are deploying the model on a research basis, Thiels said. "We're proving that we can move this from a retrospective research tool into our clinical environment and run it prospectively for validation," he said.
They are also working to further validate the model prospectively within Mayo and, this year, at a non-Mayo system, Thiels said. "We are also working on developing more advanced machine learning architectures, which appear to improve the performance even more," he added.
More information
Varghese C, et al. Enabling Digital Screening for Pancreatic Cancer using Artificial Intelligence Analysis of Disease Trajectories, American College of Surgeons (ACS) Clinical Congress 2026.
Key medical concepts
Clinical categories
OncologyCommon illnesses & Prevention Provided by American College of Surgeons Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: AI model predicts pancreatic cancer risk 3 years before diagnosis (2026, September 25) retrieved 25 September 2026 from https://medicalxpress.com/news/2026-09-ai-pancreatic-cancer-years-diagnosis.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.